Preloader
image description
July 26, 2021

2nd Virtual Symposium on

Advances in Malaria Research

8:50 AM to 5:30 PM [ U.S. Eastern Time Zone (UTC – 04:00) ]

Supporting Sponsor

image description

Welcome Message By Chair

"Welcome to our second virtual one-day symposium on the state-of-the-art in basic and translational malaria research".

Our first symposium, held in June 2020, was one of the first virtual symposia at the start of the pandemic and was a resounding success as it gave our community a forum for reconnecting with colleagues and hearing on the latest parasite and vector biology research. Our second symposium will offer the same great opportunities. We have put together an outstanding collection of speakers again this year. Our speakers will report on a broad range of technologies; more fundamentally, they will share their creative and novel perspectives on developing new therapies to control malaria.

MALARIA-2021 – A virtual one-day Symposium on Advances in Malaria Research that will bring together world-class clinicians, scientists, and investigators. This Virtual Conference provides an ideal, cost-effective format as it offers:

  • low cost: your registration supports staffing and conference hosting by USG, a non-profit
  • convenience: attend from your home or work, without risk of travel during the COVID-19 pandemic
  • focused, timely presentations on parasite-vector-host biology covering the full spectrum from atomic-level insights on targets to malaria field studies, typically before publication.

I hope that you will enjoy this symposium and benefit from networking with attendees and speakers.

Sanjay A. Desai, M.D. Ph.D.
NIAID, National Institutes of Health, Bethesda, MD, USA.

Our Speakers

Sanjay A. Desai
Sanjay A. Desai
NIAID, National Institutes of Health, MD, USA
Elizabeth Winzeler
Elizabeth Winzeler
University of California at San Diego, USA
Matthias Marti
Matthias Marti
Glasgow University
United Kingdom
Michelle M. Butler
Michelle M. Butler
Microbiotix, Inc.,
MA, USA
Peter Preiser
Peter Preiser
Nanyang Technological University, Singapore
Silvia Portugal
Silvia Portugal
Max Planck Institute for Infection Biology, Germany
Friedrich Frischknecht
Friedrich Frischknecht
Heidelberg University Medical School, Germany
Ana Rodriguez
Ana Rodriguez
New York University School of Medicine, NY, USA
R. Kip Guy
R. Kip Guy
University of Kentucky
KY, USA
Daniel Neafsey
Daniel Neafsey
Harvard T.H. Chan School of Public Health, MA, USA
Joel Vega-Rodriguez
Joel Vega-Rodriguez
NIAID, National Institutes of Health, MD, USA
Kristin D. Lane
Kristin D. Lane
Idaho State University
ID, USA
Suong T Nguyen
Suong T Nguyen
Washington University Medical Center, MO, USA
Joshua Tan
Joshua Tan
NIAID, National Institutes of Health, MD, USA

Supporting Sponsor

Kainomyx, a company founded in 2019, is committed to eradicating malaria and several other parasitic diseases worldwide. Unlike conventional approaches for developing treatments for humans infected by parasites, Kainomyx’s s strategy aims to identify therapeutics for malaria and other parasitic diseases by beginning with precise molecular information about how a drug will hinder a parasite. In addition, Kainomyx seeks equity in global health by mitigating crises that have long ravaged non-western nations and now threaten the globe due to transnational travel and alterations in climate.

Note: Listeners (students) from endemic countries are invited to apply for a registration fee waiver, supported by the meeting sponsors.
Please write us at: secretary@microbioconference.com

Testimonials

Trusted hands behind us

Our Previous Sponsors